key: cord-0855127-pksm3zxc
authors: Wright, Peter F; Prevost-Reilly, Alejandra C; Natarajan, Harini; Brickley, Elizabeth B; Connor, Ruth I; Wieland-Alter, Wendy F; Miele, Anna S; Weiner, Joshua A; Nerenz, Robert D; Ackerman, Margaret E
title: Longitudinal Systemic and Mucosal Immune Responses to SARS-CoV-2 Infection
date: 2022-02-21
journal: J Infect Dis
DOI: 10.1093/infdis/jiac065
sha: a4d7c2415dfe657f0cccbb82c846a7ac65ab647f
doc_id: 855127
cord_uid: pksm3zxc

BACKGROUND: A longitudinal study determined the breadth, kinetics, and correlations of systemic and mucosal antibody responses to SARS-CoV-2 infection. METHODS: Twenty-six unvaccinated adults with confirmed COVID-19 were followed for six months with three collections of blood, nasal secretions and stool. Control samples were obtained from 16 unvaccinated uninfected individuals. SARS-CoV-2 neutralizing and binding antibody responses were respectively evaluated by pseudovirus assays and multiplex bead arrays. RESULTS: Neutralizing antibody responses to SARS-CoV-2 were detected in serum and respiratory samples for 96% (25/26) and 54% (14/26), respectively, of infected participants. Robust binding antibody responses against SARS-CoV-2 spike protein and S1, S2, and receptor binding (RBD) domains occurred in serum and respiratory nasal secretions, but not in stool samples. Serum neutralization correlated with RBD-specific immunoglobulin (Ig)G, IgM, and IgA in serum (Spearman’s ρ=0.74, 0.66, and 0.57 respectively), RBD-specific IgG in respiratory secretions (ρ=0.52), disease severity (ρ=0.59), and age (ρ=0.40). Respiratory mucosal neutralization correlated with RBD-specific IgM (ρ=0.42) and IgA (ρ=0.63). CONCLUSIONS: Sustained antibody responses occurred after SARS-CoV-2 infection. Notably, there was independent induction of IgM and IgA binding antibody and neutralizing responses in systemic and respiratory compartments. These observations have implications for current vaccine strategies and understanding SARS-CoV-2 reinfection and transmission.

A c c e p t e d M a n u s c r i p t 4 Background SARS-CoV-2 is a beta coronavirus that was first detected in Wuhan, China, presumably following introduction from an animal reservoir. 1 The ability of SARS-CoV-2 to cause a severe respiratory illness, COVID-19, and rapidly spread through human populations has led to the most devastating pandemic in a century, resulting in an estimated 293 million infections and 5.4 million deaths globally. 2 A rapid scale-up of non-pharmaceutical public health interventions including policies with social and economic impacts (e.g. lockdowns and school and border closures), coupled with the introduction of highly effective vaccines, have limited transmission of the virus within communities. 3 However, SARS-CoV-2 infection risk persists owing to stark inequalities of global vaccine coverage, shortfalls in vaccine uptake, and the ongoing emergence of new variants of concern, such as delta, B.1.617.2 4 , and omicron, B.1.1.529. 5 Ultimately, mitigating the public health impact will require globally coordinated mass immunization campaigns with highly effective vaccines that prevent both illness and virus transmission.

An increasingly nuanced picture of the development of systemic immunity to SARS-CoV-2 has emerged for the acute and early convalescent phases of COVID-19. 6 Serum antibody to the SARS-CoV-2 spike (S) protein, and specifically to the receptor binding domain (RBD), is both critical to neutralization of the virus, 7, 8 and the strongest correlate of protection from illness. 9, 10 The role of mucosal immunity is less well articulated, although the potent nature of dimeric IgA in neutralizing SARS-CoV-2 has been described. 11 The duration of immunity to SARS-CoV-2 and correlates of protection against subsequent reinfection are not fully defined. Finally, the propensity towards serious illness in older adults despite their mounting vigorous antibody responses remains unexplained. 12 A c c e p t e d M a n u s c r i p t 5 A comprehensive approach to investigating antibody responses to SARS-CoV-2 provides insights into these critical questions. Here, we examined samples of blood, nasal wash and stool collected serially from a cohort of SARS-CoV-2-infected individuals for six months from the onset of their infection. Detailed characterization of the specificity, functionality and kinetics of the antibody responses to SARS-CoV-2 demonstrate clear distinctions in systemic and mucosal immune responses.

Twenty-six unvaccinated SARS-CoV-2-infected adults, aged 18-77 years, were enrolled at one month or more after COVID-19 diagnosis was confirmed by reverse transcription polymerase chain reaction (RT-PCR). All were followed up in the Clinical Research Unit of Dartmouth Hitchcock Medical Center (Lebanon, New Hampshire, USA) for at least six months with two additional specimen collection points at two and five-months after the initial visit ( Figure 1 ). As controls, 16 unvaccinated uninfected adults, aged 22-66 years, were sampled at a single point early in the epidemic. During the period of follow-up, no study participants received a COVID-19 vaccine, and none of the infected participants had clinical evidence of a second infection with SARS-CoV-2.

Blood, nasal secretions, and stool samples were collected at each study visit. Nasal secretions were obtained by forceful exhalation after instillation of 5 ml of normal saline into each nares in a recumbent position. Stool was self-collected either at the visit or the following day. At enrollment, a brief questionnaire evaluated the participants' severity of symptoms. Five with mild illness reported no interference with tasks of daily living. Fifteen with moderate symptoms reported having a debilitating illness that prevented the activities of A c c e p t e d M a n u s c r i p t 6 daily living with varying chief complaints of fatigue, shortness of breath, diarrheal illness, and/or fever. Six had severe enough illness to require hospitalization primarily for respiratory support. Using this information, a rank order of severity of illness was established and used to investigate correlations of immune responses and clinical symptoms. The study was approved by the Dartmouth-Hitchcock IRB and written informed consent was obtained from all participants using an approved template.

Neutralization was evaluated using a vesicular stomatitis virus (VSV) pseudovirus expressing the SARS-CoV-1 or SARS-CoV-2 S proteins, which were developed using plasmids supplied by the NIAID Rocky Mountain Laboratory. 13 Neutralizing activity was determined as a measure of functional antibody responses in serum and nasal secretions. Research Facility using a SARS-CoV-2-S lentivirus system that is the reference for measuring neutralization in COVID-19 vaccine trials. 14 The assays were found to be precisely correlated at both the first (Spearman's rho = 0.93, p < 0.0001) and second study visits (Spearman's rho = 0.91, p < 0.0001) (Supplementary Figure 1) .

Binding antibodies were evaluated using custom multiplex bead arrays. 15 For the purposes of this study, data analysis was confined to the IgG, IgM and IgA responses to components of the S protein of SARS-CoV-2. At the time of investigation, the original Wuhan SARS-CoV-2 strain was the only locally circulating virus, and homologous antigens were used in the antibody assays. The Roche Elecsys® Anti-SARS-CoV-2 immunoassay, which detects total A c c e p t e d M a n u s c r i p t 7 antibody binding responses to the N protein in serum, was performed by the Dartmouth-Hitchcock Clinical Laboratory Services.

Statistical analyses were performed using Stata, version 13, and R, version 3.6.1.

Heatmaps were made using the R package ‗pheatmap'. Features were filtered to eliminate any endpoint for which >25% of subject were within ten standard deviations of the blank used in the assay. The data was log transformed, scaled, and centered and the z-score was plotted. 16 To accommodate variation in the time of initial sampling, longitudinal data displays were stratified into 50-day blocks to 200 days after symptom onset. Linear regressions with adjustment for participant age and sex were used to evaluate mean percent differences in immune markers between infected and uninfected participants. The mean percent differences were estimated with the formula (e β − 1) × 100%, where the β coefficient represents the mean difference in log e -transformed marker level (markers with a level of 0 were recoded to 2 prior to the log e -transformation). Longitudinal patterns in log 2 serum and nasal wash neutralization and RBD-specific binding antibodies were investigated using linear multilevel mixed-effects models with participant-specific random effects, linear time trends (i.e., per 50-day units), and the variables of participant age, sex, and COVID-19 severity category. Multiplicative interaction was investigated using likelihood ratio tests. Pairwise correlations between antibody concentrations and neutralization titers in serum, nasal secretions, and stool samples at the time of the initial visit as well as participant age and severity rank order (i.e., from 1 (least symptomatic) to 26 (most severe) were estimated with Spearman rank correlation coefficients and visualized in matrices using the -corrplot‖ R package version 0.88. 17 Spearman rank correlation coefficients and scatterplots were also used to compare SARS-CoV-2 pseudovirus neutralization between the VSV and lentivirus assays. 

We performed a correlation analysis to define relationships between sample types, assays, disease severity and age at the first study visit (the complete data set is shown in Supplemental Figure 3 ). In the serum, strong positive correlations were found between measurements of virtually all binding antibodies to SARS-CoV-2 S proteins in all Ig classes, and neutralization (Spearman's Rho > 0.55 for all). We focused on RBD responses in Figure   5 . The height of RBD-specific IgG antibodies in serum was moderately positively correlated with age (Spearman's rho = 0.36) but more strongly correlated with the ranking of severity of disease (Spearman's rho = 0.56). Serum RBD IgM antibodies showed no correlation with age (Spearman's rho = 0.10) but a strong correlation with severity of disease (Spearman's 

We followed the evolution of systemic and mucosal upper respiratory tract immunity over a 6-month period following infection with SARS-CoV-2. Despite the relatively small number of SARS-CoV-2-infected volunteers studied, we were able to demonstrate correlations of SARS-CoV-2-speciifc antibody responses with each other, and with sample type, age, and severity of illness. Naïve individuals provided a comparator for interpreting responses to SARS-CoV-2 infection. An earlier report by our group used a systems biology approach to A c c e p t e d M a n u s c r i p t 13 define antibody functionality by coronavirus type, epitope and Ig class at the initial time point. 15 In the current study, we incorporated data from sequential sampling to provide information on persistence of antibody responses with a focus on interrelationships of the mucosal and systemic immune compartments.

Our results demonstrate that induction of a SARS-CoV-2-specific antibody response occurs both systemically and in the respiratory tract., Enteric antibody was not seen. This is consistent with poliovirus findings -enteric antibody response to oral attenuated vaccine, while vigorous in infants and young children, was absent in adults. 21 The SARS-CoV-1 responses were not suggestive of an anamnestic response as they were low titer, not IgM, not sustained, and had no relationship to height of SARS-CoV-2 neutralizing antibody or to age.

Serum and mucosal neutralizing antibody titers showed a marked and uniform decline during follow-up. In contrast, other studies have shown more variable declines in titer. 22 This decline correlated with decline in serum IgM and IgA binding antibodies to RBD, the key recognition site for neutralizing antibodies, 6 and suggests that IgM and/or IgA may be a major component of serum neutralization in the early convalescent period as indicated by other recent work. 23, 24 Supporting this is that IgM depletion, in contrast to depletion of IgA or IgG, markedly lowers serum neutralizing titers. 25 The decline in neutralizing titer contrasts with our ability to isolate greater numbers of neutralizing monoclonal antibodies with increasing avidity over time from eight members of this same cohort. 26 The sustainability of serum neutralizing antibody responses is a shared concern between SARS CoV-2 natural infection and vaccination. [28] [29] [30] The half-life of serum neutralizing antibody after mRNA vaccination was 55 days 30 Relatively few articles have addressed mucosal response to SARS-CoV-2 infection. 32, 33 When done, most have reported using techniques that do not optimally address an IgAmediated response. 34 35 SARS-CoV-2 proved highly effective at inducing mucosal IgA in the respiratory tract. Although high levels of protection from illness are seen with systemically administered SARS-CoV-2 vaccines, concerns remain about the extent to which these vaccines limit virus replication in the upper respiratory tract. 36 This concern has been heightened by the recent demonstrations of extensive replication 37 and transmission of the SARS-CoV-2 delta variant. 38 There is evidence that mRNA-based vaccines canconfer a substantial degree of protection against infection. 39 However, animal models consistently demonstrate that vaccination targeted to the induction of mucosal antibody may be critical in limiting SARS-CoV-2 replication on challenge and, by implication, interrupting transmission. 40, 41 Severity of COVID-19 disease has an important positive correlation with the height of neutralizing responses in the serum. 42 From our data the following conclusions can be drawn.

 Nasal neutralizing and IgA spike antibodies have no correlation with severity of illness.

 Severity of illness is the strongest correlate with increasing serum neutralizing and IgG spike immune responses.

We highlight the influence of age and severity of illness on the immune response-following SARS CoV-2 infection. Older individuals have markedly higher mortality from COVID- 19, 43 yet, have higher serum neutralizing antibody responses as compared to younger individuals. 32 , The converse-that immune responses wane with age-is generally accepted 44 as is the case with SARS-CoV-2 mRNA vaccines. 30 Vaccines are given in higher doses (e.g.

A c c e p t e d M a n u s c r i p t 16 for influenza) or with novel adjuvants in older adults to induce comparable immune responses to those seen in younger adults. 45 If heightened virus replication stimulates an enhanced antibody response, it would be reasonable to expect mucosal responses in the upper respiratory tract to also be higher in the sicker individuals. . This was not the case in our study. Our results broadly align with previous work which does not show a correlation between the height of virus shedding and severity of symptoms, though the more symptomatic individuals appeared to be infected for longer periods of time. 46, 47 As attention is paid to the diminishing neutralizing antibody responses over time postvaccination, it is important to recognize that this is also seen after natural infection and that other components of the immune response to infection or vaccination may be equally important in providing protection against more serious illness. In particular, the induction of mucosal IgA, which is locally produced and can uniquely transcytose across the epithelial cell barrier can be postulated to be critical in the inactivation of viruses like SARS-CoV-2 that replicate primarily in the respiratory tract and must be a target for vaccine-induced immunity. 48, 49 A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t SARS-CoV-2-specific neutralization, RBD binding antibody levels, participant age and severity (i.e., in increasing rank order), and binding antibody levels at the first study visit in SARS-CoV-2infected participants (n=25). Pairwise spearman rank correlation coefficients of serum and

A new coronavirus associated with human respiratory disease in China

Comparisons between countries are essential for the control of COVID-19

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

SARS-CoV-2 Omicron spike mediated immune escape, infectivity and cell-cell fusion bioRxiv 2021

Adaptive immunity to SARS-CoV-2 and COVID-19

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Evidence for antibody as a protective correlate for COVID-19 vaccines

Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Evaluation of cell-based and surrogate SARS-CoV-2 neutralization assays

Distinct Features and Functions of Systemic and Mucosal Humoral Immunity Among SARS-CoV-2 Convalescent Individuals. Front Immunol

pheatmap: Pretty Heatmaps

Visualization of a Correlation Matrix

mRNA Vaccination Induces Durable Immune Memory to SARS-CoV-2 with Continued Evolution to Variants of Concern

Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19

Prolonged presence of SARS-CoV-2 viral RNA in faecal samples

Mucosal immunity to poliovirus

COVID-19 Healers Sustain Anti-SARS-CoV-2 Antibody Production

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2

Antibody Attributes that Predict the Neutralization and Effector Function of Polyclonal Responses to SARS-CoV-2. medRxiv

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitope

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants Science

Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Virus-specific IgA in serum, saliva, and tears of children with measles

Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients

Optimal collection and assay of upper respiratory specimens for determination of mucosal immune responses to influenza. Options for the Control of Influenza III

Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants

COVE Study Group Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Shedding of Infectious SARS-CoV-2 Despite Vaccination when the Delta Variant is Prevalent -Wisconsin

Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings -Barnsy

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

A Single-Dose Intranasal ChAd Vaccine Protects Upper and Lower Respiratory Tracts against SARS-CoV-2

Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines

Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans

Clinical Characteristics of Coronavirus Disease 2019 in China

Immunosenescence and human vaccine immune responses

Comparative Immunogenicity of Several Enhanced Influenza Vaccine Options for Older Adults: A Randomized, Controlled Trial

Viral dynamics of acute SARS-CoV-2 infection and applications to diagnostic and public health strategies

Quantitative detection of SARS-CoV-2 RNA in nasopharyngeal samples from infected patients with mild disease

Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants

The scent of a vaccine

A c c e p t e d M a n u s c r i p t